Experimental KRRO-110 trial for rare lung condition halted early
Disease control
Terminated
This study tested an experimental drug called KRRO-110 in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can cause lung and liver damage. The goal was to check safety and how the drug moves through the body. However, the trial w…
Phase: PHASE1, PHASE2 • Sponsor: Korro Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC